Use of LHRH-agonists as adjuvant therapy for breast cancer

Author: Cuzick, Jack

Source: Expert Opinion on Therapeutic Targets, Volume 12, Number 8, August 2008 , pp. 1065-1071(7)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Individual data was collected for 11,906 women in 16 randomised trials evaluating a luteinising-hormone-releasing hormone (LHRH) agonist either alone, as an addition to tamoxifen or chemotherapy or in place of chemotherapy. When used alone these agents led to a large (28%) relative decrease in recurrence, which was not significant (p = 0.08) due to the small number of patients randomised. Addition of LHRH-agonist to tamoxifen, chemotherapy or both, reduced recurence by 13% (p = 0.02), and when used alone these agents showed similar efficacy to chemotherapy. The largest effect after chemotherapy was seen in women aged ≤ 40 years. Most of the chemotherapy was CMF-based, so comparisons with more modern chemotherapy would be useful. In addition, the optimum duration of treatment is unknown.

Keywords: breast cancer; chemotherapy; LHRH; tamoxifen

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14728222.12.8.1065

Publication date: 2008-08-01

More about this publication?